[Congressional Record Volume 153, Number 72 (Thursday, May 3, 2007)]
[House]
[Pages H4461-H4464]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




    TECHNOLOGY INNOVATION AND MANUFACTURING STIMULATION ACT OF 2007

  The SPEAKER pro tempore. Pursuant to House Resolution 350 and rule 
XVIII, the Chair declares the House in the Committee of the Whole House 
on the state of the Union for the further consideration of the bill, 
H.R. 1868.

                              {time}  1426


                     In the Committee of the Whole

  Accordingly, the House resolved itself into the Committee of the 
Whole House on the state of the Union for the further consideration of 
the bill (H.R. 1868) to authorize appropriations for the National 
Institute of Standards and Technology for fiscal years 2008, 2009, and 
2010, and for other purposes, with Mrs. Tauscher (Acting Chairman) in 
the chair.
  The Clerk read the title of the bill.
  The Acting CHAIRMAN. When the Committee of the Whole rose earlier 
today, amendment No. 3 offered by the gentleman from Illinois (Mr. 
Manzullo) had been disposed of.


                  Amendment No. 2 Offered by Mr. Wynn

  The Acting CHAIRMAN. It is now in order to consider amendment No. 2 
printed in House Report 110-118.
  Mr. WYNN. Madam Chairman, I offer an amendment.
  The Acting CHAIRMAN. The Clerk will designate the amendment.
  The text of the amendment is as follows:

       Amendment No. 2 offered by Mr. Wynn:
       In section 204, in the proposed section 28(b)(1), insert 
     ``(including any technological application that uses 
     biological systems, living organisms, or derivatives thereof, 
     to make or modify products or processes for specific use)'' 
     after ``enabling technologies''.

  The Acting CHAIRMAN. Pursuant to House Resolution 350, the gentleman 
from Maryland (Mr. Wynn) and a Member opposed each will control 5 
minutes.
  The Chair recognizes the gentleman from Maryland.
  Mr. WYNN. Madam Chair, the amendment that I am proposing will make 
sure that the biotechnology research and innovation are included under 
TIP's funding objectives by expanding the definition of enabling 
technologies in section 204 of the bill to include ``any technological 
application that uses biological systems, living organisms or 
derivatives thereof to make or modify products or processes for 
specific use.''
  Biotechnology is an emerging segment of the technology sector often 
overlooked as an excellent source of manufacturing jobs and research 
and development. The biotechnology industry is a driving force in the 
Maryland economy and a rising sector of the American economy.
  In the United States, the biotechnology industry has created more 
than 200 new therapies and vaccines, including products to treat 
cancer, diabetes, HIV/AIDS and anti-autoimmune disorders.
  The industry continues to develop innovative therapies over 400 
products are currently in clinical trials targeting over 200 diseases. 
The biotechnology industry is comprised of mostly small start-ups that 
don't have an existing stream of revenue and are years away from 
product commercialization. It takes at least 8 years, and then up to 
$1.2 billion to get a biotechnology therapy approved.
  It is these small companies, many of which will never see a product 
come to market or turn a product that are undertaking the bulk of early 
development gambles and working toward innovative cures. In fact, small 
biotech companies account for two-thirds of the industry's pipeline.
  In 2005, there were 1,400 biotech companies in the United States, but 
only 329 were publicly traded. The majority of the Biotechnology 
Industry Organization's (BIO) members are small companies that have 
fewer than 50 employees.
  The U.S. is the leader in biotechnology. The number of products in 
the late stage pipeline in the U.S. has double the number of products 
in the E.U. This is largely due to the fact that per capita biotech R&D 
in the U.S. is 574 percent higher than in the E.U.

                              {time}  1430

  My State of Maryland is a leader among States in biotechnology 
research and innovation, and Maryland-based businesses will benefit 
greatly from the funding awarded under this bill. But not only 
Maryland; other small startup companies in the biotech industry will 
benefit by inclusion of this bill.
  I believe it is a simple, straightforward amendment that just expands 
and clarifies the fact that biotechnology companies should be included, 
and I ask support for the amendment.
  Mr. WU. Madam Chairman, will the gentleman yield?
  Mr. WYNN. I would be happy to yield.
  Mr. WU. Madam Chairman, on the Science and Technology Committee we 
are keenly aware of the importance of the biotechnology industry to our 
economy. We also know that the

[[Page H4462]]

growth in our biotech industry is largely due to early Federal 
investment and support in this field, and I am pleased to support the 
gentleman from Maryland's amendment.
  Mr. WYNN. Madam Chairman, I thank the chairman for his support.
  Madam Chairman, I yield back the balance of my time.
  Mr. EHLERS. Madam Chairman, I rise to say I have no objection to the 
amendment, and I yield back the balance of my time.
  The Acting CHAIRMAN. The question is on the amendment offered by the 
gentleman from Maryland (Mr. Wynn).
  The amendment was agreed to.
  The Acting CHAIRMAN. The question is on the committee amendment in 
the nature of a substitute, as amended.
  The committee amendment in the nature of a substitute, as amended, 
was agreed to.
  The Acting CHAIRMAN. Under the rule, the Committee rises.
  Accordingly, the Committee rose; and the Speaker pro tempore (Mr. 
Scott of Virginia) having assumed the chair, Mrs. Tauscher, Acting 
Chairman of the Committee of the Whole House on the state of the Union, 
reported that that Committee, having had under consideration the bill 
(H.R. 1868) to authorize appropriations for the National Institute of 
Standards and Technology for fiscal years 2008, 2009, and 2010, and for 
other purposes, pursuant to House Resolution 350, she reported the bill 
back to the House with an amendment adopted by the Committee of the 
Whole.
  The SPEAKER pro tempore. Under the rule, the previous question is 
ordered.
  Is a separate vote demanded on any amendment to the amendment 
reported from the Committee of the Whole? If not, the question is on 
the amendment.
  The amendment was agreed to.
  The SPEAKER pro tempore. The question is on the engrossment and third 
reading of the bill.
  The bill was ordered to be engrossed and read a third time, and was 
read the third time.


       Motion to Recommit Offered by Mr. English of Pennsylvania

  Mr. ENGLISH of Pennsylvania. Mr. Speaker, I offer a motion to 
recommit.
  The SPEAKER pro tempore. Is the gentleman opposed to the bill?
  Mr. ENGLISH of Pennsylvania. In its present form, I am.
  The SPEAKER pro tempore. The Clerk will report the motion to 
recommit.
  The Clerk read as follows:

       Mr. English of Pennsylvania moves to recommit the bill H.R. 
     1868 to the Committee on Science and Technology with 
     instructions to report back the same forthwith with an 
     amendment. The amendment is as follows:
       In section 204, insert ``(a) Amendment.--'' before 
     ``Section 28 of''.
       In section 204, add at the end the following new 
     subsection:
       (b) Limiting Authorizations in Any Year Following a Year 
     With an On-Budget (excluding Social Security) Deficit and an 
     Off-Budget (Social Security) Surplus.--
       (1) Limitation.--Notwithstanding any other provision of 
     this Act, for any fiscal year for which funds are authorized 
     to be appropriated under this Act that immediately follows a 
     fiscal year in which the Government has an actual on-budget 
     deficit and an actual off-budget surplus, the amount of money 
     authorized to be appropriated under this Act for the 
     Technology Innovation Program under section 28 of the 
     National Institute of Standards and Technology Act, as 
     amended by subsection (a) of this section, shall not exceed 
     the amount appropriated for that Program, or the predecessor 
     Advanced Technology Program, for the preceding fiscal year.
       (2) Definitions.--For purposes of this subsection--
       (A) the term ``actual on-budget deficit'' means a fiscal 
     year during which total outlays of the Government excluding 
     outlays from Social Security programs exceeds total receipts 
     of the Government excluding receipts from Social Security 
     programs;
       (B) the term ``actual off-budget surplus'' means a fiscal 
     year in which receipts from Social Security programs exceeds 
     outlays from Social Security programs; and
       (C) the term ``Social Security programs'' means the Federal 
     Old-Age and Survivors Insurance Trust Fund and the Federal 
     Disability Insurance Trust Fund.

  Mr. WU. Mr. Speaker, I reserve a point of order against the motion to 
recommit.
  The SPEAKER pro tempore. A point of order is reserved.
  The gentleman from Pennsylvania is recognized for 5 minutes.
  Mr. ENGLISH of Pennsylvania. Mr. Speaker, in my view, there are three 
Grand Canyons in America. One is famous, and it is in Arizona and, I 
think, familiar to most in the West. Another is well known in the 
eastern United States, and it is in Wellsboro, Pennsylvania.
  The third has opened up since the last election. And here, Mr. 
Speaker, I am referring to the grand canyon, the gap, between the 
rhetoric of the Democratic Caucus in the House of Representatives, as 
witnessed on the floor of the House in the last Congress and in 
previous Congresses, and the policies of the Democratic Congress since 
being sworn in in this Congress.
  I remember, Mr. Speaker, fondly, some of the speeches that were given 
on the floor of Congress on behalf of the Social Security system. Some 
fierce, even lachrymose presentations that any additional funding for 
any new priority inevitably would be at the expense of the balance of 
the Social Security system, which is seriously in the red. In other 
words, new spending, because we were running a deficit, was inevitably 
at the expense of the Social Security system. I have heard our friends 
on the other side of the aisle make the case repeatedly in previous 
Congresses to restrict spending because additional funds would be 
coming out of the Social Security system.
  But, Mr. Speaker, since the election, Democrats seem to have muted 
these concerns and Democratic actions have been very different.
  Mr. Speaker, I propose to give our friends on the other side of the 
aisle an opportunity to bridge the Grand Canyon. I propose to give the 
majority a small, perhaps symbolic, but very important opportunity to 
reach out and express their commitment to fiscal policies that preserve 
the Social Security balance for what it was intended for: to fund 
retirement savings.
  Mr. Speaker, by commingling our Social Security surplus with our 
deficit-ridden general fund, we potentially expose our Social Security 
system to risk by shielding our policymakers from their spending 
decisions to the full consequences and the full balance sheet. The time 
has come for us to change that practice.
  Specifically, this motion says that the funding authorized for the 
Advanced Technology Program will be capped at the previous year's 
appropriated amount until such time as the Social Security surplus is 
not used to foot part of the bill.
  There is no doubt that the ATP program has great merit. But I think 
we have to ask ourselves, Mr. Speaker, is increasing funding for the 
program more important than saving the Social Security surplus for 
future beneficiaries?
  Mr. Speaker, I serve on the committee of jurisdiction, and recently 
we had an opportunity to hear from the Social Security actuaries one 
more time that the Social Security system is at risk, is under enormous 
pressure, and that the time has come to take decisive steps to make it 
solvent so that its promise can be fulfilled to the next generation. 
What we are proposing here today is maybe to begin this process in a 
small way and create an opportunity for all of our friends in this 
institution to go on record firmly in an important policy decision and 
make it clear that we are not going to raid the Social Security fund in 
the future.
  This is a very clear issue. It is a very simple issue. It is an 
opportunity to cut past the rhetoric and, frankly, create an 
opportunity for us to do something very significant on one of the major 
issues facing the country.
  Mr. Speaker, I hope everyone in this body will join me in supporting 
this very important initiative on behalf of the Social Security fund.
  Mr. Speaker, I yield back the balance of my time.
  Mr. WU. Mr. Speaker, I withdraw my point of order, and I rise in 
strong opposition to the motion to recommit.
  The SPEAKER pro tempore. The gentleman is recognized for 5 minutes.
  Mr. WU. Mr. Speaker, we have heard much talk about the Social 
Security trust fund and the solvency of Social Security. But in the 
time that I have been here, in 8 years, the solvency of Social Security 
has been increased by approximately 8 years, and that increase is 
because of American economic growth. It was projected at 34 years of 
solvency. It is currently projected at 42 years of solvency, and that

[[Page H4463]]

is based on conservative, conservative estimates. The reason why there 
has been that increase in the solvency period of Social Security is 
because of economic growth.
  There is nothing more important to the American economy and our 
competitiveness than the legislation that we are considering today.
  The motion to recommit which the gentleman offers would fundamentally 
gut this legislation and prevent us from investing in the most 
productive of technologies, a traditional role which the Federal 
Government has played to support research and early-stage development, 
not commercialization, but early-stage development. By prohibiting 
those activities with this cap, what in essence would happen is our 
rate of economic growth would be slackened, our ability to manufacture 
jobs would be decreased.
  This is a motion to recommit which would gut the bill, and I urge its 
defeat.
  Mr. Speaker, I yield back the balance of my time.
  The SPEAKER pro tempore. Without objection, the previous question is 
ordered on the motion to recommit.
  There was no objection.
  The SPEAKER pro tempore. The question is on the motion to recommit.
  The question was taken; and the Speaker pro tempore announced that 
the noes appeared to have it.
  Mr. ENGLISH of Pennsylvania. Mr. Speaker, on that I demand the yeas 
and nays.
  The yeas and nays were ordered.
  The SPEAKER pro tempore. Pursuant to clause 9 of rule XX, the Chair 
will reduce to 5 minutes the minimum time for any electronic vote on 
the question of passage.
  The vote was taken by electronic device, and there were--yeas 190, 
nays 216, not voting 26, as follows:

                             [Roll No. 300]

                               YEAS--190

     Aderholt
     Akin
     Alexander
     Bachmann
     Bachus
     Baker
     Barrett (SC)
     Bartlett (MD)
     Barton (TX)
     Biggert
     Bilbray
     Bilirakis
     Bishop (UT)
     Blackburn
     Blunt
     Boehner
     Bonner
     Bono
     Boozman
     Boustany
     Brady (TX)
     Brown (SC)
     Brown-Waite, Ginny
     Buchanan
     Burgess
     Burton (IN)
     Buyer
     Calvert
     Camp (MI)
     Campbell (CA)
     Cannon
     Cantor
     Capito
     Carter
     Castle
     Chabot
     Coble
     Cole (OK)
     Conaway
     Crenshaw
     Culberson
     Davis (KY)
     Davis, David
     Davis, Tom
     Deal (GA)
     Dent
     Diaz-Balart, L.
     Diaz-Balart, M.
     Donnelly
     Doolittle
     Drake
     Dreier
     Duncan
     Ellsworth
     Emerson
     English (PA)
     Everett
     Fallin
     Feeney
     Ferguson
     Flake
     Forbes
     Fortenberry
     Fossella
     Foxx
     Frelinghuysen
     Gallegly
     Garrett (NJ)
     Gerlach
     Gilchrest
     Gillmor
     Gohmert
     Goode
     Goodlatte
     Granger
     Hall (TX)
     Hastings (WA)
     Hayes
     Heller
     Hensarling
     Herger
     Hill
     Hobson
     Hoekstra
     Hulshof
     Inglis (SC)
     Issa
     Johnson (IL)
     Johnson, Sam
     Jones (NC)
     Jordan
     Keller
     King (IA)
     King (NY)
     Kingston
     Kirk
     Kline (MN)
     Knollenberg
     Kuhl (NY)
     LaHood
     Lamborn
     Latham
     LaTourette
     Lewis (CA)
     Lewis (KY)
     Linder
     LoBiondo
     Lucas
     Lungren, Daniel E.
     Mack
     Manzullo
     Marchant
     McCarthy (CA)
     McCaul (TX)
     McCotter
     McCrery
     McKeon
     Mica
     Miller (FL)
     Miller (MI)
     Miller, Gary
     Moran (KS)
     Murphy, Tim
     Musgrave
     Myrick
     Neugebauer
     Nunes
     Pence
     Peterson (PA)
     Petri
     Pickering
     Pitts
     Platts
     Poe
     Porter
     Price (GA)
     Pryce (OH)
     Putnam
     Ramstad
     Regula
     Rehberg
     Reichert
     Renzi
     Reynolds
     Rogers (AL)
     Rogers (KY)
     Rogers (MI)
     Rohrabacher
     Ros-Lehtinen
     Roskam
     Royce
     Ryan (WI)
     Sali
     Saxton
     Schmidt
     Sensenbrenner
     Sessions
     Shadegg
     Shays
     Shimkus
     Shuler
     Shuster
     Simpson
     Smith (NE)
     Smith (NJ)
     Smith (TX)
     Souder
     Stearns
     Sullivan
     Taylor
     Terry
     Thornberry
     Tiahrt
     Tiberi
     Turner
     Upton
     Walberg
     Walden (OR)
     Walsh (NY)
     Wamp
     Weldon (FL)
     Weller
     Westmoreland
     Whitfield
     Wicker
     Wilson (NM)
     Wilson (SC)
     Wolf
     Young (AK)
     Young (FL)

                               NAYS--216

     Abercrombie
     Ackerman
     Allen
     Altmire
     Andrews
     Arcuri
     Baca
     Baird
     Baldwin
     Barrow
     Bean
     Becerra
     Berkley
     Berman
     Berry
     Bishop (GA)
     Bishop (NY)
     Blumenauer
     Boren
     Boswell
     Boucher
     Boyd (FL)
     Boyda (KS)
     Braley (IA)
     Brown, Corrine
     Capps
     Capuano
     Cardoza
     Carnahan
     Carney
     Castor
     Chandler
     Clarke
     Clay
     Cleaver
     Clyburn
     Cohen
     Conyers
     Cooper
     Costello
     Courtney
     Cramer
     Crowley
     Cuellar
     Cummings
     Davis (AL)
     Davis (CA)
     Davis (IL)
     Davis, Lincoln
     DeFazio
     DeGette
     Delahunt
     DeLauro
     Dicks
     Dingell
     Doggett
     Doyle
     Edwards
     Ehlers
     Ellison
     Emanuel
     Eshoo
     Etheridge
     Farr
     Filner
     Frank (MA)
     Giffords
     Gillibrand
     Gonzalez
     Gordon
     Green, Al
     Green, Gene
     Grijalva
     Gutierrez
     Hall (NY)
     Hare
     Harman
     Hastings (FL)
     Herseth Sandlin
     Higgins
     Hinchey
     Hinojosa
     Hirono
     Hodes
     Holden
     Holt
     Honda
     Hooley
     Hoyer
     Inslee
     Israel
     Jackson (IL)
     Jackson-Lee (TX)
     Jefferson
     Johnson (GA)
     Jones (OH)
     Kagen
     Kanjorski
     Kaptur
     Kennedy
     Kildee
     Kilpatrick
     Kind
     Klein (FL)
     Kucinich
     Langevin
     Lantos
     Larsen (WA)
     Larson (CT)
     Lee
     Levin
     Lewis (GA)
     Lipinski
     Loebsack
     Lofgren, Zoe
     Lowey
     Lynch
     Mahoney (FL)
     Maloney (NY)
     Markey
     Marshall
     Matheson
     Matsui
     McCarthy (NY)
     McCollum (MN)
     McDermott
     McGovern
     McIntyre
     McNerney
     McNulty
     Meehan
     Meek (FL)
     Meeks (NY)
     Melancon
     Michaud
     Miller (NC)
     Miller, George
     Mitchell
     Mollohan
     Moore (KS)
     Moore (WI)
     Moran (VA)
     Murphy (CT)
     Murphy, Patrick
     Murtha
     Nadler
     Napolitano
     Neal (MA)
     Oberstar
     Obey
     Olver
     Pallone
     Pascrell
     Pastor
     Payne
     Perlmutter
     Peterson (MN)
     Pomeroy
     Price (NC)
     Rahall
     Rangel
     Reyes
     Rodriguez
     Ross
     Roybal-Allard
     Ruppersberger
     Rush
     Ryan (OH)
     Salazar
     Sanchez, Linda T.
     Sanchez, Loretta
     Sarbanes
     Schakowsky
     Schiff
     Schwartz
     Scott (GA)
     Scott (VA)
     Serrano
     Sestak
     Shea-Porter
     Sherman
     Sires
     Skelton
     Slaughter
     Smith (WA)
     Snyder
     Solis
     Space
     Spratt
     Stark
     Stupak
     Sutton
     Tauscher
     Thompson (CA)
     Thompson (MS)
     Tierney
     Towns
     Udall (CO)
     Udall (NM)
     Van Hollen
     Velazquez
     Visclosky
     Walz (MN)
     Wasserman Schultz
     Waters
     Watson
     Watt
     Waxman
     Weiner
     Welch (VT)
     Wexler
     Wilson (OH)
     Woolsey
     Wu
     Wynn
     Yarmuth

                             NOT VOTING--26

     Brady (PA)
     Butterfield
     Carson
     Costa
     Cubin
     Davis, Jo Ann
     Engel
     Fattah
     Franks (AZ)
     Gingrey
     Graves
     Hastert
     Hunter
     Jindal
     Johnson, E. B.
     Lampson
     McHenry
     McHugh
     McMorris Rodgers
     Ortiz
     Paul
     Pearce
     Radanovich
     Rothman
     Tancredo
     Tanner

                              {time}  1505

  Ms. BERKLEY, Mr. COHEN and Mr. JOHNSON of Georgia changed their vote 
from ``yea'' to ``nay.''
  Ms. ROS-LEHTINEN and Messrs. BILBRAY, KIRK, PICKERING, WOLF and 
GILCHREST changed their vote from ``nay'' to ``yea.''
  So the motion to recommit was rejected.
  The result of the vote was announced as above recorded.
  The SPEAKER pro tempore (Mr. Scott of Virginia). The question is on 
the passage of the bill.
  The question was taken; and the Speaker pro tempore announced that 
the ayes appeared to have it.


                             Recorded Vote

  Mr. WU. Mr. Speaker, I demand a recorded vote.
  A recorded vote was ordered.
  The SPEAKER pro tempore. This will be a 5-minute vote.
  The vote was taken by electronic device, and there were--ayes 385, 
noes 23, not voting 24, as follows:

                             [Roll No. 301]

                               AYES--385

     Abercrombie
     Ackerman
     Aderholt
     Alexander
     Allen
     Altmire
     Andrews
     Arcuri
     Baca
     Bachmann
     Bachus
     Baird
     Baker
     Baldwin
     Barrow
     Bartlett (MD)
     Barton (TX)
     Bean
     Becerra
     Berkley
     Berman
     Berry
     Biggert
     Bilbray
     Bilirakis
     Bishop (GA)
     Bishop (NY)
     Bishop (UT)
     Blackburn
     Blumenauer
     Blunt
     Boehner
     Bonner
     Bono
     Boozman
     Boren
     Boswell
     Boucher
     Boustany
     Boyd (FL)
     Boyda (KS)
     Brady (TX)
     Braley (IA)
     Brown (SC)
     Brown, Corrine
     Brown-Waite, Ginny
     Buchanan
     Burgess
     Buyer
     Calvert
     Camp (MI)
     Cannon
     Capito
     Capps
     Capuano
     Cardoza
     Carnahan
     Carney
     Carson
     Castle
     Castor
     Chabot
     Chandler
     Clarke
     Clay
     Cleaver
     Clyburn
     Cohen
     Cole (OK)
     Conaway
     Conyers
     Cooper
     Costello
     Courtney
     Cramer
     Crenshaw
     Crowley
     Cuellar
     Culberson
     Cummings
     Davis (AL)
     Davis (CA)
     Davis (IL)
     Davis (KY)
     Davis, David
     Davis, Lincoln
     Davis, Tom
     Deal (GA)
     DeFazio
     DeGette
     Delahunt
     DeLauro
     Dent
     Diaz-Balart, L.
     Diaz-Balart, M.
     Dicks
     Dingell
     Doggett
     Donnelly
     Doolittle
     Doyle
     Drake
     Dreier
     Edwards
     Ehlers
     Ellison
     Ellsworth
     Emanuel
     Emerson
     Eshoo
     Etheridge
     Everett
     Fallin
     Farr
     Feeney
     Ferguson
     Filner
     Forbes
     Fortenberry
     Fossella
     Frank (MA)
     Frelinghuysen
     Gallegly
     Garrett (NJ)
     Gerlach

[[Page H4464]]


     Giffords
     Gilchrest
     Gillibrand
     Gillmor
     Gingrey
     Gohmert
     Gonzalez
     Goode
     Goodlatte
     Gordon
     Granger
     Green, Al
     Green, Gene
     Grijalva
     Gutierrez
     Hall (NY)
     Hall (TX)
     Hare
     Harman
     Hastings (FL)
     Hastings (WA)
     Hayes
     Heller
     Herger
     Herseth Sandlin
     Higgins
     Hill
     Hinchey
     Hinojosa
     Hirono
     Hobson
     Hodes
     Hoekstra
     Holden
     Holt
     Honda
     Hooley
     Hoyer
     Hulshof
     Inglis (SC)
     Inslee
     Israel
     Issa
     Jackson (IL)
     Jackson-Lee (TX)
     Jefferson
     Johnson (GA)
     Johnson (IL)
     Jones (NC)
     Jones (OH)
     Jordan
     Kagen
     Kanjorski
     Kaptur
     Keller
     Kennedy
     Kildee
     Kilpatrick
     Kind
     King (NY)
     Kirk
     Klein (FL)
     Kline (MN)
     Knollenberg
     Kucinich
     Kuhl (NY)
     LaHood
     Langevin
     Lantos
     Larsen (WA)
     Larson (CT)
     Latham
     LaTourette
     Lee
     Levin
     Lewis (CA)
     Lewis (GA)
     Lewis (KY)
     Linder
     Lipinski
     LoBiondo
     Loebsack
     Lofgren, Zoe
     Lowey
     Lucas
     Lungren, Daniel E.
     Lynch
     Mahoney (FL)
     Maloney (NY)
     Manzullo
     Marchant
     Markey
     Marshall
     Matheson
     Matsui
     McCarthy (CA)
     McCarthy (NY)
     McCaul (TX)
     McCollum (MN)
     McCotter
     McCrery
     McDermott
     McGovern
     McIntyre
     McKeon
     McNerney
     McNulty
     Meehan
     Meek (FL)
     Meeks (NY)
     Melancon
     Mica
     Michaud
     Miller (MI)
     Miller (NC)
     Miller, Gary
     Miller, George
     Mitchell
     Mollohan
     Moore (KS)
     Moore (WI)
     Moran (KS)
     Moran (VA)
     Murphy (CT)
     Murphy, Patrick
     Murphy, Tim
     Murtha
     Musgrave
     Myrick
     Nadler
     Napolitano
     Neal (MA)
     Neugebauer
     Nunes
     Oberstar
     Obey
     Olver
     Pallone
     Pascrell
     Pastor
     Payne
     Perlmutter
     Peterson (MN)
     Peterson (PA)
     Petri
     Pickering
     Pitts
     Platts
     Poe
     Pomeroy
     Porter
     Price (GA)
     Price (NC)
     Pryce (OH)
     Putnam
     Rahall
     Ramstad
     Rangel
     Regula
     Rehberg
     Reichert
     Renzi
     Reyes
     Reynolds
     Rodriguez
     Rogers (AL)
     Rogers (KY)
     Rogers (MI)
     Rohrabacher
     Ros-Lehtinen
     Roskam
     Ross
     Roybal-Allard
     Ruppersberger
     Rush
     Ryan (OH)
     Ryan (WI)
     Salazar
     Sanchez, Linda T.
     Sanchez, Loretta
     Sarbanes
     Saxton
     Schakowsky
     Schiff
     Schmidt
     Schwartz
     Scott (GA)
     Scott (VA)
     Serrano
     Sessions
     Sestak
     Shays
     Shea-Porter
     Sherman
     Shimkus
     Shuler
     Shuster
     Simpson
     Sires
     Skelton
     Slaughter
     Smith (NE)
     Smith (NJ)
     Smith (TX)
     Smith (WA)
     Snyder
     Solis
     Souder
     Space
     Spratt
     Stark
     Stearns
     Stupak
     Sullivan
     Sutton
     Tauscher
     Taylor
     Terry
     Thompson (CA)
     Thompson (MS)
     Thornberry
     Tiahrt
     Tiberi
     Tierney
     Towns
     Turner
     Udall (CO)
     Udall (NM)
     Upton
     Van Hollen
     Velazquez
     Visclosky
     Walberg
     Walden (OR)
     Walsh (NY)
     Walz (MN)
     Wamp
     Wasserman Schultz
     Waters
     Watson
     Watt
     Waxman
     Weiner
     Welch (VT)
     Weldon (FL)
     Weller
     Westmoreland
     Wexler
     Whitfield
     Wicker
     Wilson (NM)
     Wilson (OH)
     Wilson (SC)
     Wolf
     Woolsey
     Wu
     Wynn
     Yarmuth
     Young (AK)
     Young (FL)

                                NOES--23

     Akin
     Barrett (SC)
     Burton (IN)
     Campbell (CA)
     Cantor
     Carter
     Coble
     Duncan
     English (PA)
     Flake
     Foxx
     Franks (AZ)
     Hensarling
     Johnson, Sam
     King (IA)
     Kingston
     Lamborn
     Mack
     Pence
     Royce
     Sali
     Sensenbrenner
     Shadegg

                             NOT VOTING--24

     Brady (PA)
     Butterfield
     Costa
     Cubin
     Davis, Jo Ann
     Engel
     Fattah
     Graves
     Hastert
     Hunter
     Jindal
     Johnson, E. B.
     Lampson
     McHenry
     McHugh
     McMorris Rodgers
     Miller (FL)
     Ortiz
     Paul
     Pearce
     Radanovich
     Rothman
     Tancredo
     Tanner


                Announcement by the Speaker Pro Tempore

  The SPEAKER pro tempore (during the vote). Members are advised 2 
minutes remain in this vote.

                              {time}  1513

  Mr. KING of Iowa changed his vote from ``aye'' to ``no.''
  So the bill was passed.
  The result of the vote was announced as above recorded.
  A motion to reconsider was laid on the table.
  Stated for:
  Mr. MILLER of Florida. Mr. Speaker, I missed rollcall vote No. 301 on 
May 3, 2007. It was a vote on H.R. 1868, the Technology Innovation and 
Manufacturing Stimulation Act.
  If present, I would have voted rollcall vote No. 301, ``aye.''

                          ____________________